Crescent Biopharma prices $125.0 million stock offering, expected to close July 16
Crescent Biopharma agreed on July 14, 2026 to sell 8,094,793 ordinary shares and pre-funded warrants for 525,897 more shares in a public offering, with gross proceeds expected to be about $125.0 million. The company says the net proceeds, together with existing cash, should fund projected operating expenses, working capital and capital expenditures into the second half of 2028, but the sale adds shares outstanding for existing holders.
Key points
- Ordinary shares priced at $14.50 each; pre-funded warrants priced at $14.499 each, for 525,897 shares in total
- Expected net proceeds of about $115.9 million, or about $133.5 million if the underwriters' 30-day option for 1,293,103 additional shares is exercised in full
- Offering expected to close on July 16, 2026, subject to customary closing conditions
- Company estimates cash will fund operations into the second half of 2028
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 15, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.